Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Puma Biotechnology Inc (NYSE:PBYI)

94.84
Delayed Data
As of Aug 28
 +6.21 / +7.01%
Today’s Change
79.29
Today|||52-Week Range
278.14
-49.89%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.1B

Company Description

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010. Its predecessor company, Innovative Acquisitions Corp was originally incorporated in Delaware in April 2007 as a shell company and later acquired and merged itself into Puma Biotechnology, Inc. in October 2011. The company is headquartered in Los Angeles, CA.

Contact Information

Puma Biotechnology, Inc.
10880 Wilshire Boulevard
Los Angeles California 90024
P:(424) 248-6500
Investor Relations:
142424865002011

Employees

Shareholders

Mutual fund holders56.89%
Other institutional38.36%
Individual stakeholders30.74%

Top Executives

Alan H. AuerbachChairman, President & Chief Executive Officer
Charles R. EylerTreasurer & Senior Vice President-Administration
Richard Paul BryceSenior VP-Clinical Research & Development
Cheryl CollettController
Mariann OhanesianSenior Director-Investor Relations